Stay updated with breaking news from Therapeutic Vector Evolution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Initial interim landmark data analysis will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and Degeneration 2024...
4D-710 has demonstrated promising, reproducible, CFTR expression significantly above normal levels for seven patients across Cohorts 1 & 2 and durable improvement or stabilization of quality of life...
Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize AAV-delivered CRISPR/Cas-based therapeutics for up to six product candidates...
Designation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile in patients with wet age-related macular...
Initial interim landmark data analysis to be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial, on Saturday, February 3, 2024 at 4:20 p.m. ET ...